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INTRODUCTION
Immunoglobulin A nephropathy (IgAN) is the most com-
mon form of primary glomerulonephritis and is an impor-
tant cause of end-stage renal disease requiring renal replace-
ment therapy (1). Although the pathogenetic mechanism of
IgAN is still controversial, a great body of evidence suggests
that cytokines such as tumor necrosis factor (TNF) and inter-
leukin play an important role in the renal injury of IgAN
(2, 3).
TNF and TNF are potent cytokines which are associ-
ated with the inflammatory response (4). TNF is involved
in the initiation or progression of renal injury (5). Increased
expression of TNF has been demonstrated in vivo in several
animal models of glomerulonephritis (6). TNF and TNF
genes are closely linked and tandemly arranged in the human
genome and map between class I and class III regions of major
histocompatibility complex (MHC) in humans (4). The loca-
tion of TNF genes within the MHC raised a possibility that
some MHC-linked inflammatory diseases might be related
to genetic variations inside the TNF locus. A genomic poly-
morphism within the TNF locus influences plasma TNF
concentration (7). It is known that there are at least two poly-
morphisms in the class III region controlling TNF produc-
tion. One is at position -308 base pairs in the promoter region
of the TNF gene (7), for which allele 2 (TNF2) is associated
with higher constitutive and inducible levels of TNF (8).
The other is in intron 2/exon 3 of the TNF gene, with the
two polymorphic alleles variably associated with high and
low levels of TNF secretion by mononuclear cells, depend-
ing on the population under investigation (9, 10). However,
the role of TNF gene polymorphism in IgAN is not clear as
yet.
We evaluated the G →A transition polymorphism of the
TNF and TNF gene with NcoI restriction fragment length
analysis and their clinical significances in seventy-six patients
with primary IgAN confirmed by renal biopsy.
MATERIALS AND METHODS
A total of 76 patients (38 males, 38 females; mean age,
30.4 yr) diagnosed as IgA nephropathy by renal biopsy were
included in this study. We excluded patients with glomeru-
lonephritis associated with diabetes mellitus, systemic lupus
erythematosus, or hepatitis B or C virus. One hundred healthy
volunteers (49 males, 51 females; mean age, 48.2 yr) were
recruited during an annual physical examination at Soon-
chunhyang Chonan Hospital (Chonan, Korea) as normal
controls.
Genomic DNA was extracted by DNA extraction column
(QIAmp blood kit; Qiagen, Venlo, The Netherlands) from
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Is Tumor Necrosis Factor Genotype (TNFA2/TNFA2) a Genetic
Prognostic Factor of an Unfavorable Outcome in IgA Nephropathy?
The purpose of this study was to examine whether there are the associations be-
tween TNF and TNF gene polymorphisms and the development and progres-
sion of Ig A nephropathy (IgAN). A cross-sectional study on TNF and TNF gene
polymorphisms by polymerase chain reaction with restriction fragment length poly-
morphisms was performed on 76 patients with primary IgAN confirmed by renal
biopsy and 100 healthy controls. The allele with G→A substitution was designated
as TNFA2 for the TNF gene and TNFB2 for the TNF gene. A patient in whom
dialysis treatment was started or whose serum creatinine became double or over
during the follow-up duration was designated as a “progressor” . The TNFA2/
TNFA2 genotype was more prevalent in the progressor than in the non-pregres-
sor group (20.0 vs 3.3%, p<0.05). Clinical factors such as serum creatinine, sys-
tolic and diastolic blood pressure (p<0.001, respectively) were higher and patho-
logic factor such as Grade IV or V renal lesions was more prevalent (p<0.01) in
the progressor than in the non-progressor group. Therefore, TNFA2/TNFA2 geno-
type may be a risk factor for the progression of IgAN.
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peripheral blood. Polymerase chain reaction (PCR) was per-
formed using the primer sets under the conditions previous-
ly described (7, 11): sense primers (TNF : 5′ -AGG CAA
TAG GTT TTG AGG GCC AT-3′ ; TNF : 5′ -CCG TGC
TTC GTG CTT TGG ACT A-3′ ), antisense primers
(TNF : 5′ -TCC TCC CTG CTC CGA TTC CG-3′ ; TNF :
5′ -AGA GGG GTG GAT GCT TGG GTT C-3′ ), and a
GeneAmp PCR machine (Perkin Elmer 9600; Perkin Elmer,
Norwalk, CT) were used. Products of 107 and 782 bp were
generated for TNFA and TNFB, respectively. The amplified
PCR products were digested with NcoI and analysed by gel
electrophoresis. For TNF , primers were designated to incor-
porate a polymorphic site at a position -308 bp of the TNF
gene into a NcoI restriction site. Restriction digests generat-
ed products of 87 and 20 bp for allele 1 (TNFA1) and 107
bp for allele 2 (TNFA2). The 782 bp fragment amplified
across intron 2 of the TNF gene also incorporates a poly-
morphic NcoI site, which generates fragments of 782 bp for
TNFB2 and 586 plus 196 bp for TNFB1. Ethidium bro-
mide staining of the gel demonstrated the original 782 bp
fragment (homozygous patients for allele TNFB2, lacking
the NcoI site), three fragments of 782, 586, and 196 bp of
length (heterozygous patients), or two fragments of 586 and
196 bp of size (homozygous patients for the allele TNFB1)
(Fig. 1). The clinical parameters at renal biopsy and the lat-
est follow-up data were collected. A patient in whom dialy-
sis treatment was started or whose serum creatinine became
double or over during the follow-up duration was designat-
ed as  “progressor” .
Data were expressed as mean±SD for the age, follow-up
duration, 24-hr proteinuria, serum creatinine, systolic and
diastolic blood pressures, hematocrit, and cholesterol. Statis-
tical analyses of genotype distributions and allele frequen-
cies were performed by an analysis of variance test or  2 test.
p-value was calculated by the Student’ s t-test for continuous
variables or Fisher’ s exact test for categorical variables. p<0.05
was considered to be statistically significant’ s.
RESULTS
Polymorphism of the TNF gene 
The genotype of TNF distribution was as follows: in the
76 patients with IgAN, 45 patients (59.2%) had the TNFA1/
TNFA1 genotype, 26 patients (34.2%) had the TNFA1/
TNFA2 genotype, and 5 patients (6.6%) had the TNFA2/
TNFA2 genotype. There was no significant difference in the
distribution of genotype or allele frequencies of the TNF
gene between IgAN patients and control subjects (Table 1).
There was no significant difference in clinical parameters
which included the age, 24-hr proteinuria, serum creatinine,
hematocrit, cholesterol, and systolic and diastolic BP at renal
biopsy among the three TNF genotypes. And neither was
there any difference in the follow-up duration of the three
Values are expressed as number (percent). There were no significant
statistical differences between the groups.
Control IgA
nephropathy
TNF Genotype TNFA1/TNFA1 65 (65.0) 45 (59.2)
TNFA1/TNFA2 31 (31.0) 26 (34.2)
TNFA2/TNFA2 4 (4.0) 5 (6.6)
Allele TNFA1 161 (80.5) 116 (76.3)
TNFA2 39 (19.5) 36 (23.7)
TNF Genotype TNFB1/TNFB1 4 (4.0) 8 (10.5)
TNFB1/TNFB2 57 (57.0) 37 (48.7)
TNFB2/TNFB2 39 (39.0) 31 (40.8)
Allele TNFB1 65 (32.5) 53 (34.9)
TNFB2 135 (67.5) 99 (65.1)
Table 1. Distribution of tumor necrosis factor (TNF) and  TNF
gene frequencies in control subjects and patients with IgA
nephropathy
Values are expressed as mean±S.D. or percent. p-value was calculat-
ed by ANOVA for continuous variables or Fisher’ s exact test for cate-
gorical variables. *p<0.05. A patient in whom dialysis treatment was
started or whose serum creatinine became double or over during the
follow-up duration was designated as  “progressor” .
TNFA1/TNFA1
(n=45)
TNFA1/TNFA2
(n=26)
TNFA2/TNFA2
(n=5)
At renal biopsy
Age (yr) 31.4±10.2 31.9±10.2 36.8±10.7
Proteinuria (mg/24 hr) 2,428±2,737 3,164±3,519 5,240±3,150
Serum creatinine (mg/dL) 1.2±0.5 1.1±0.4 1.2±0.6
Systolic BP (mmHg) 131.2±22.6 138.1±18.8 144±18.1
Diastolic BP (mmHg) 83.8±15.3 85.8±12.1 94±15.2
Hematocrit (%) 40.0±5.3 40.0±4.2 43.8±7.5
Cholesterol (mg/dL) 216.7±54.9 202.1±49.1 199.2±52.2
At follow-up
Progressor (%) 22.2 7.7* 60.0*
Table 2. Comparison of clinical characteristics in patients with
IgA nephropathy at renal biopsy and the lastest follow-up by
TNF genotypes
1   2   3
107 bp
4   5   6
TNF
TNFA2/TNFA2
TNFA1/TNFA1
TNFA1/TNFA2
TNFB2/TNFB2
TNFB1/TNFB1
TNFB1/TNFB2
TNF
Fig. 1. Electrophoresis of the PCR product of the TNF and TNF
genes. Lane 1 is a homozygote of TNFA2, lane 2 is a homozy-
gote of TNFA1, and lane 3 is a heterozygote of TNFA1 and TNFA2.
Lane 4 is a homozygote of TNFB2, lane 5 is a homozygote of
TNFB1, and lane 6 is a heterozygote of TNFA1 and TNFA2.
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TNF genotypes (55.3±40.6 vs 65.8±34.1 vs 71.2±35.4
months). However, the prevalence of a progressor among
the three genotypes was significantly different (TNFA2/
TNFA2 vs TNFA1/TNFA2, 60.0 vs 7.7%, p<0.05, Table 2).
Polymorphism of the TNF gene 
The genotype of TNF distribution were as follows: in the
patients with IgAN, 8 patients (10.5%) had the TNFB1/
TNFB1 genotype, 37 patients (48.7%) had the TNFB1/
TNFB2 genotype, and 31 patients (40.8%) had the TNFB2/
TNFB2 genotype. There was no significant difference in
the distribution of the genotype of the TNF gene between
the IgAN and control subjects (Table 1). The overall allele
frequency of TNF was also shown in Table 1. There were
no significant differences in the clinical parameters which
included the age, 24-hr proteinuria, serum creatinine, hema-
tocrit, cholesterol, systolic and diastolic BP at renal biopsy
(Table 3), follow-up duration and the frequency of those
belonging to the progressor group among the three TNF
genotypes (52.0±27.4 vs 57.8±37.9 vs 64.6±41.2
months).
Prognostic factors of progression of IgAN
The follow-up duration was not significantly different be-
tween the non-progressor and progressor groups (54.8±36.9
vs 80.0±37.3 months). The systolic and diastolic blood
pressure at renal biopsy were significant higher in the progres-
sor group than non-progressor group (p<0.001, respectively,
Table 4). The proteinuria at renal biopsy was higher in the
progressor group than non-progressor group, however, it did
not reach the statistical significance (Table 4). There were
no significant differences in the age, hematocrit, and choles-
terol at renal biopsy between the groups (Table 4). The preva-
lence of Grade IV or V renal lesions (12) was higher in the
progressor group than non-progressor group (p<0.01, Table
4). The serum creatinines at renal biopsy (p<0.001, Table 4)
and at the latest follow-up (1.28±1.13 vs 6.09±2.11, p<
0.001) were higher in the progressor group than in the non-
progressive group. The rate of decline of renal function was
calculated as [(1/serum creatinine at renal biopsy-1/serum cre-
atinine at the latest follow-up)/months of follow-up duration]
×100. It was significantly higher in the progressor group
than non-progressor group (p<0.001, Table 4). In the progres-
sor group, 12 patients with end-stage renal disease were in-
Values are expressed as mean±S.D. or percent. Rate of decline of
renal function was calculated as [(1/serum creatinine at renal biopsy-
1/serum creatinine at the latest follow-up)/months of follow-up duration]
×100. +Grading system according to Lee (12) was available only for
49 patients due to insufficient kidney biopsy material. p-value was cal-
culated by Student’ s t-test for continuous variables or Fisher’ s exact
test for categorical variables, *p<0.05, 
� p<0.01, 
� p<0.001.
Non-progressor
(n=61)
Progressor 
(n=15)
Clinical Factors
Age (yr) 30.0±8.1 33.0±8.5
Proteinuria (mg/24 hr) 2,497±3,162 4,179±2,894
Serum creatinine (mg/dL) 1.02±0.34 1.53±0.56
�
Systolic BP (mmHg) 131.5±19.7 156.7±20.6
�
Diastolic BP (mmHg) 81.9±12.7 101.1±16.2
�
Hematocrit (%) 40.1±4.9 42.5±7.8
Cholesterol (mg/dL) 207.0±53.7 219.7±40.8
Rate of decline of renal function 0.155±0.356 0.796±0.419
�
Pathologic Factor
Class IV or V lesions (%)+ 12.2 50.0
�
Genetic Factor
TNFA2/TNFA2 genotype (%) 3.3 20.0*
Table 4. Clinical predictors of progression of renal failure in
patients with IgA nephropathy
Values are expressed as mean±S.D. or percent. Statistical difference
was calculated by ANOVA for continuous variables or Fisher's exact
test for categorical variables. There were no significant statistical differ-
ences among the groups. A patient in whom dialysis treatment was
started or whose serum creatinine became double or over during the
follow-up duration was designated as  “progressor” .
TNFB1/TNFB1
(n=8)
TNFB1/TNFB2
(n=37)
TNFB2/TNFB2
(n=31)
At renal biopsy
Age (yr) 32.1±10.4 30.6±10.7 32.0±8.4
Proteinuria (mg/24 hr) 3,000±2,384 3,137±3,696 2,529±2,415
Serum creatinine (mg/dL) 1.44±0.83 1.07±0.40 1.1±0.38
Systolic BP (mmHg) 143.3±25.0 131.7±20.4 136.6±21.3
Diastolic BP (mmHg) 86.7±15.1 84.7±12.8 85.5±16.2
Hematocrit (%) 40.6±4.2 38.9±4.6 42.0±5.5
Cholesterol (mg/dL) 223.3±43.9 213.7±55.0 201.7±51.4
At follow-up
Progressor (%) 25.0 10.8 29.0
Table 3. Comparison of clinical characteristics in patients with
IgA nephropathy at renal biopsy and the lastest follow-up by
TNF genotypes
0% 20% 40% 60% 80% 100%
Progressor
Non-progressor
Fig. 2. Distribution of TNF genotypes in the patients with IgA
nephropathy. A progressor means a patient whose serum crea-
tinine became double or over during the follow-up duration more
than three years. TNFA2/TNFA2 genotype was more prevalent in
the progressor group (p<0.05).
TNFA2/TNFA2 TNFA1/TNFA2 TNFA1/TNFA1
*754 E.-Y. Lee, D.-H. Yang, K.-Y. Hwang, et al.
cluded. Nine patients had the TNFA1/TNFA1 genotype,
2 patients had the TNFA1/ TNFA2 genotype, and 1 patient
had the TNFA2/TNFA2 genotype. The TNFA2/TNFA2
genotype was more prevalent in the progressor group than
non-progressor group (p<0.05, Table 4, Fig. 2).
DISCUSSION
TNF is a proinflammatory cytokine that has been in-
volved in certain forms of immune-mediated renal injury,
including IgAN (5). TNF is synthesized by glomerular
cells or circulating macrophage/monocytes (13, 14). TNF
activates mesangial cells to release procoagulants, plasmino-
gen activator, and plasminogen activator inhibitor (13). In-
creased expression of TNF has been demonstrated in vivo in
several animal models of glomerulonephritis including murine
lupus models (6). The administration of TNF potentiates
renal injury in IgAN, murine lupus models, and anti-GBM
antibody disease. The location of TNF genes within the MHC
raised a possibility that some MHC-linked inflammatory
diseases might be related to genetic variations inside the
TNF locus. The polymorphism of gene encoding TNF at
position -308 in the promoter region involving a transition
of guanidine to adenosine has been characterized (11). The -
308A polymorphism (TNFA2) is associated with an increase
of TNF transcription (15), which may predispose humans
to the occurrence of inflammatory diseases. Carriage of the
TNFA2 allele has been shown to be associated with several
inflammatory diseases (16). There was no significant differ-
ence in the distribution of genotype or allele frequencies of
the TNF gene between IgAN patients and control subjects
in this study. Our result was similar to previous reports (17).
Therefore, we speculate that the TNF gene polymorphism
is not associated with the development of IgAN.
The clinical course of IgAN is extremely variable. The
clinical predictors including impairment of renal function,
severe proteinuria, and arterial hypertension at presentation
have been known as of an unfavorable outcome of IgAN (18).
Our data supported these previous observations. The clinical
parameters including serum creatinine, systolic and diastolic
blood pressure at renal biopsy and the prevalence of Grade
IV or V renal pathologic lesions were significantly higher in
the progressor group than in the non-progressor group in
this study. These also support previous results (18).
Besides clinical and pathologic prognostic factors, the in-
terest to search for genetic markers such as HLA-B35 or
specific genotype of angiotensin converting enzyme (ACE)
polymophism for progression of IgAN has increased. How-
ever, no study has confirmed the association between the
progression of IgAN and the presence of specific HLA or
ACE genotypes (18). Also, the prognostic significance of
TNF gene polymorphism in IgAN patients on the progres-
sion of the disease has not been described so far. The patients
with IgAN who had a progressive disease were more com-
monly observed in the subgroup of the TNFA2/TNFA2 geno-
type and the TNFA2/TNFA2 genotype was more prevalent
in the progressor group than in the non-progressor group in
our study. This is the first report, to our knowledge, that the
TNFA2/TNFA2 genotype is a genetic prognostic factor in
IgAN.
There are some limitations in this study. Firstly, the num-
ber of patients with TNFA2/TNFA2 was too small to per-
form multiple logistic regression analysis. Secondly, we used
the changes of 1/(serum creatinine) as the parameter of renal
progression of IgAN because other parameters such as crea-
tinine clearance were not available. Thirdly, this was a cross-
sectional study, and we obtained the data retrospectively.
Therefore, there might have been some bias for the inclusion
of patients. Fourthly, all study subjects are Koreans in our
study, therefore, we could not rule out possible ethnic differ-
ences. Lastly, we did not analyze the influence of various treat-
ments.
The TNF gene is closely linked to TNF , tandemly
arranged in the human genome, and map between class I
and class III regions of MHC in humans (4). The two NcoI-
defined TNFB alleles, which differ in structure and in the
level of TNF inducibility, might be relevant for MHC-
associated predispositions for autoimmune diseases (8). The
TNFB1 allele is strongly linked to the altered production of
TNF and the variant polypeptide structure might contribute
to disease susceptibility of this haplotype. It is conceivable
that an allelically varying TNF response of activated T lym-
phocytes might contribute to the inflammatory mechanism
of local autoimmune reactions (8). Previous reports demon-
strated an association between a NcoI TNF polymorphism
and immune-mediated glomerulonephritis including mem-
branous nephropathy and IgAN. They explained this asso-
ciation by linkage disequilibrium with extended MHC hap-
lotypes, however, whether the TNF polymorphism per se
is involved in disease susceptibility is not clear in IgAN (10).
We could not find any evidence for the association between
TNF polymorphism and IgAN in this study.
In conclusion, this is the first report showing the associa-
tion between the specific TNF genotype and the progression
of IgAN. The polymorphisms in the TNF and TNF gene
were not associated with the development of IgAN, however,
the TNFA2/TNFA2 genotype of the TNF gene was more
commonly found in patients with IgAN who had a progres-
sive disease than those with the TNFA1/TNFA1 or TNFA1/
TNFA2 genotype. Therefore, although there were some limi-
tations in this study, it is suggested that the TNFA2/TNFA2
genotype may be a risk factor for the progression of IgAN.
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